Injections to slow vision loss from dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests an investigational eye injection (RO7965032) for people with geographic atrophy, a form of dry age-related macular degeneration that causes progressive vision loss. The goal is to see if the treatment can slow further vision loss and preserve sight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have geographic atrophy from dry age-related macular degeneration.
- Your vision in the study eye must be at least 20/40 (read most letters on an eye chart).
- You can see well enough to have detailed images taken of the back of your eye.
- You have not had 'wet' macular degeneration (new, leaky blood vessels) in either eye.
- You have no other major eye diseases (like diabetic eye swelling, retinal detachment, or a macular hole) in the study eye.
- You can see in both eyes (not monocular) and have no serious eye infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This trial tests an experimental drug called KRIYA-825 (also known as VV-14295) for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. The study aims to see if the treatment is safe and can help slow the progression of the disease.
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This trial is testing a new eye implant (TO-O-1007) to see if it's safe and helps slow vision loss from geographic atrophy, a late stage of dry age-related macular degeneration (AMD). The implant is placed inside the eye and releases medicine over time.
Hear when a new Geographic Atrophy Secondary to Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.